Unleashing The Potential of Macrophages
Oligoimmune is pioneering a new era of macrophage therapeutics, founded by serial entrepreneurs from MD Anderson Cancer Center and Weill Cornell Medicine. We translate world-class science into precisely engineered therapies designed to reprogram the immune system to combat cancer and fibrosis. Built for speed and scale, our platform is designed to advance rapidly, manufacture reliably, and deliver meaningful outcomes for patients.
Our Proprietary Platform
We’ve built a unique human ex vivo platform and a macrophage-targeting mechanism to de-risk programs with primary human data and accelerate candidates toward IND. Our approach enables a single ASO to multiplex key macrophage pathways, and it can be applied across oncology and fibrosis, therefore unlocking multiple assets from one engine.
Multiplex Targeting
An approach that modulates multiple macrophage pathways at once rather than relying on a single target.
First-in-Class Targets
We have identified unique, first-in-class macrophage targets that enables selective modulation of pathogenic macrophage subsets.
TNBC, Pulmonary Fibrosis
Our current focus is on two critical areas of unmet medical need: triple-negative breast cancer (TNBC) and pulmonary fibrosis.
Partnering & Careers
We are actively seeking strategic partnerships with biopharma to accelerate our myeloid-directed assets. We are also hiring macrophage biologists.